#syneos | Explore Tumblr posts and blogs

mostlysignssomeportents · 2 years ago

Text

Big Business can't stop its illegal, fantastically lucrative gossiping

Seven years ago, I called Leonard Cohen’s Everybody Knows “the perfect anthem for our times.”

Everybody knows the war is over Everybody knows the good guys lost Everybody knows the fight was fixed The poor stay poor, the rich get rich That’s how it goes Everybody knows

https://memex.craphound.com/2016/11/11/leonard-cohen-wrote-the-perfect-anthem-for-our-times/

If you’d like an essay-formatted version of this post to read or share, here’s a link to it on pluralistic.net, my surveillance-free, ad-free, tracker-free blog:

https://pluralistic.net/2023/03/16/compulsive-cheaters/#rigged

That was just after Cohen died, and while the world seems to want to settle on Hallelujah as his totemic song, Everybody Knows keeps inserting itself into the discourse, in the most toxic, hope-draining way possible. Whenever some awful scandal involving the great and the good breaches, we’re told that “everybody knew” already, so let’s move on.

This current has been running through our society for decades now. Remember when the Snowden leaks hit and a yawning chorus of nihilists told us that they knew already and so should anyone else with the smallest iota of sophistication? Back then Jay Rosen coined a rejoinder to this counsel of despair: “Don’t savvy me”:

https://twitter.com/jayrosen_nyu/status/344825874362810369

Everybody knows. It’s what we heard after the Panama Papers. Swissleaks. Luxleaks. The Paradise Papers. Everybody knows! It’s what the nothing-to-see-here crowd said about Propublica’s explosive IRSLeaks, back in 2021:

https://pluralistic.net/2021/06/15/guillotines-and-taxes/#carried-interest

The leaks revealed the tax-dodges of the richest and most powerful people in America, which were jaw-dropping in their audacity and shamelessness. Sure, maybe you suspected that the 400 richest people in America paid less tax than you — but did you really guess that the means by which they did this was through taking massive deductions on their elite hobbies?

https://pluralistic.net/2022/04/13/taxes-are-for-the-little-people/#leona-helmsley-2022

Maybe “everybody knows” that the game is rigged, but did you know how? Like, did you know that REITs — a tax shelter for mom-and-pop investors who buy an income property for their retirement — have become a primary vehicle for gutting unions at hotels, slashing wages and imposing brutal, dangerous working conditions?

https://pluralistic.net/2022/03/01/reit-modernization-act/#reit-makes-might

The leaks are cumulative. By combining data from one leak with another, we can build out a far more detailed picture of the conspiracy — and it is a conspiracy — among the utlrawealthy and their Renfields in the law, real-estate and accounting trades to duck their responsibilities and mound ever-more treasure on their hoards.

Take the Jersey Offshore leaks (2020), comprising the internal memos of La Hougue, a fantastically crooked firm of fixers on the Isle of Jersey, one of the lawless tax-crime jurisdictions that the UK pretends it has no control over. La Hougue has a playbook, 11 tactics for lying about your taxes. The remarkable thing about these 11 tactics is how flimsy they are, how easy it is to penetrate their lies. When Parliament says it can’t possibly do anything about the criminal havens in the Channel, remember the Jersey Offshore leaks and remind yourself that not even Parliament is that credulous. They know. Everybody knows:

https://pluralistic.net/2021/06/20/la-hougue/#complexity

Why do working people think the Democrats are just another party for the ultra-rich? Maybe it’s Pelosi’s relentless opposition to meaningful curbs on insider trading. Or maybe it’s the kinds of politicians that the Democratic Machine likes to rally behind — like Tali Farhadian Weinstein, who raised millions in 2021, in large-money donations from Democratic finance-sector donors in her bid to become the DA of Manhattan. Farhadian Weinstein and her husband have more than $100m in annual income, and yet, paid no federal tax in 2013, 2015 and 2017. In 2014, they paid $6,584:

https://pluralistic.net/2021/06/17/quis-custodiet-irs/#trumps-taxes

Propublica isn’t done with the IRS Files. Today, they published a long investigation into ultra-rich corporate executives who buy and sell their competitors’ stock for massive profits with suspiciously precise timing. The data comes from 1099-B filings, which brokerages file with the IRS with each trade, but which the IRS doesn’t share with the SEC:

https://www.propublica.org/article/secret-irs-files-trading-competitors-stock

Here are some examples:

Ohio billionaire August Troendle, CEO of Medpace, repeatedly bought and sold shares of $Syneos — his company’s archrival, timing the transactions with a management shakeup that dropped the stock by 16% in one day, and an SEC investigation that crushed Syneos’s stock by 25%. His precision timing made him at least $2.3m in profit.

Isaac Larian, CEO of Bratz-maker MGA, made $28m trading shares in Mattel, MGA’s nemesis and frequent litigant — during a period when Mattel stock crashed by 57% (!). Larian boasts that “I made a LOT more money shorting Mattel stock than they did running a $4.5 billion toy company.”

Larian’s trades also involved some very precise timing. Sometimes, he took positions just before his own company announced its upcoming products, and others positions immediately preceded major disclosures from Mattel. Larian’s subordinates told Propublica that he is “is a boss with an endless appetite for information about his company and its competitors, constantly grilling subordinates on minutiae about the industry.”

Larian couldn’t explain the timing of these trades. His lawyer told Propublica that it was “false and defamatory” to suggest that he “possessed material, nonpublic information that Larian knew was obtained in breach of a duty.”

Next up is Gerald Boelte, founder and chair of the massive oil company LLOG. LLOG partners with other companies for its oil drilling. Companies like Stone Energy. Boelte bought a huge position in Stone the day before the company’s 2015 earnings report, in which they revealed an increase their reserves’ value, pulling in a 65% one day profit. He’d never bought shares in Stone before.

Boetle told Propublica, “I do not and have never traded on any material, non-public information of competitors, business partners or others… Any implication that I was investing based upon advance knowledge is therefore clearly false.”

Jim Sankey is CEO of Invue. He bought $3.2m worth of shares in his rival Checkpoint, while checkpoint was in secret negotiations to be acquired by CCL Industries. Sankey was already thoroughly connected to Checkpoint, having sold a $150m product line to them in 2007. There’s no record that he’d ever traded Checkpoint before. He made $2.3m. Sankey says “he did not know Checkpoint was going to be acquired.” He says that his company was not approached by Checkpoint as a potential acquirer.

Barry Wish was a board member of Ocwen, a company he co-founded. After the Great Financial Crisis, Ocwen bid unsuccessfully to buy $215b worth of Bank of America mortgages. The winning bidder was Nationstar. Three weeks before Nationstar’s winning bid was announced, Wish bought $600k worth of Nationstar shares. After the bid was announced, he sold them for for a $157k profit.

Wish told Propublica that he never traded competitors’ stock: “No, not at all.” Propublica read him the details of the trade from his leaked 1099-B. He said “You might see it, but I don’t have any recollection” and hung up.

Steven Grossman is a cardboard heir — a nepobaby who inherited Southern Container Corp from his grandpa. After he sold the company to Rock-Tenn for $1b in 2013, he stayed on as a senior exec. Over the next 5 years, he traded large blocks of shares in Rock-Tenn’s competitors, companies like Temple-Inland, a company that he made a 37% profit on after its acquisition was announced in 2011, one week after Grossman started buying its shares.

Grossman falsely told Propublica, “I haven’t traded stock since then.” IRS records show that Grossman continued to trade. Grossman also told Propublica that he had no role with Rock-Tenn, despite being on their payroll for five years. When asked about his extremely lucky timing buying and selling Temple-Inland, he said “That was 10 years ago” and hung up.

As Propublica’s Robert Faturechi and Ellis Simani write, Securities regulations have their origins in the crash of 1929, and the subsequent collapse in confidence in markets and capitalism, the sense that the system was rigged for the wealthy and political insiders. That is a pretty good summation of sentiment today:

https://pluralistic.net/2023/03/15/mon-dieu-les-guillotines/#ceci-nes-pas-une-bailout

It’s not just that corporate executives are corrupt, it’s that they’re lavishly, shamelessly, endlessly, incorrigibly corrupt. Take Canadian Pacific and Kansas City Southern, the sixth- and seventh-largest Class I railroads in the USA, whose merger was just approved by the Surface Transportation Board.

There are plenty of good reasons for the STB to have blocked this merger. The rail industry is already excessively concentrated, and its top execs are so convinced that they’re both too big to fail and too big to jail that they’re rendering entire towns permanently uninhabitable in order to eke out a few more points in profit:

https://pluralistic.net/2023/02/11/dinah-wont-you-blow/#ecp

But there are specific reasons to have blocked this merger, starting with the whistleblower report about CP and KCS executives illegally coming together for a three-day “retreat” at The Breakers hotel in Palm Beach, a notorious site for Republican operatives to collude with the business lobby:

https://prospect.org/infrastructure/transportation/2023-03-16-canadian-pacific-kansas-city-southern-rail-merger/

As Luke Goldstein writes for The American Prospect, both companies spent millions in 2020 and 2022 on campaign contributions to “grease the skids” for the merger — in particular, ensuring that the combined company could transport Alberta tar sands oil (the filthiest, most energy intensive oil in the world) to US ports.

Though the STB was informed of the illegal meeting — in which the two companies behaved as though the merger had already been finalized — STB chair Martin Oberman told Goldstein that the Board did not write to the companies for an explanation before waving through their merger.

Instead, Oberman dismissed the complaint on the grounds that “Railroads have to be able to talk to one another to function.” Typically this takes place over a free phone call, though — not on a three-day executive junket at a hotel where the rooms run $1,500/night.

Oberman knows what happened at that meeting.

Everybody knows.

It comes as no surprise to learn that before FTX imploded and destroyed the savings of its depositors, it paid out $3b to its top executives, including the criminal Sam Bankman-Fried:

https://gizmodo.com/sbf-ftx-crypto-sam-bankman-fried-1850232043

It comes as no surprise that Silicon Valley Bank paid out bonuses to its execs and employees hours before it collapsed:

https://www.cnbc.com/2023/03/11/silicon-valley-bank-employees-received-bonuses-hours-before-takeover.html

Everybody knows.

It’s comforting to think that the tax code loopholes that the ultrawealthy exploit are an epiphenomenon of complexity, an unavoidable consequence of the technical requirements of a big regulation that spans 300m+ people. But the truth is, the loopholes in the US tax code were inserted by politicians who got massive campaign contributions from donors who directly benefited from those loopholes. Senator Ron Johnson got $20m from the owners of Uline (Dick and Liz Uihlein) and roofing magnate Diane Hendricks, then he blocked the Trump tax bill until his fellow lawmakers inserted a loophole that produced $215m for the Uihleins and Hendricks, in just the first year:

https://pluralistic.net/2021/08/11/the-canada-variant/#shitty-man-of-history-theory It’s not even surprising that a sitting US Senator amended a bill to give hundreds of millions of dollars to billionaires who gave him tens of millions of dollars.

Everybody knows. It’s weirdly comforting to think that everyday people vote for demagogue wreckers because Facebook hired a legion of evil sorcerers to fashion a mind-control ray out of Big Data and AI, but Facebook lies about everything, and everyone who ever claimed to have a mind-control ray was a liar.

Maybe people vote for demagogue wreckers because they believe the system is rotten, and maybe they believe the system is rotten because the system is rotten. Maybe the self-described evil sorcerers of Big Tech aren’t “hacking our dopamine loops” — maybe they’re just helping opportunists target people who are justifiably angry:

https://onezero.medium.com/how-to-destroy-surveillance-capitalism-8135e6744d59

The problem with this explanation is that it requires “progressive” parties to actually do stuff to demonstrate that they are on the side of people, not the side of paperclip-maximizing immortal colony organisms and the corporate executives who pretend to run them:

https://twitter.com/thehill/status/1184004730722217984

I try to have hope — that is, I try to believe that if we can only make changes to our material circumstances, however small they may seem, that we might attain a new vantagepoint that reveals more possible changes within our grasp:

https://gen.medium.com/hope-not-optimism-943e88291b

Some days, it’s hard to have hope. Some days, it’s so obvious that everybody knows, all that I can muster is fury. Fury is not a full substitute for hope, but it’ll do. It’s a far superior alternative to the fatalism that “everybody knows” and thus nothing can be done.

Some fights you win, and other fights, you just fight, because surrender isn’t an option. Everybody knows, right? If everybody knows, then everybody might just decide to do something about it.

Next Monday (Mar 20), I’m doing a remote talk for the Ostrom Workshop’s Beyond the Web Speaker Series.

[Image ID: A smoke-filled room lit by candles. Around a large formal table sit various 19th century gentlemen-type people. One of them stands and reads from a memo. The shadow he casts is in the shape of a dollar-sign.]

51 notes · View notes

roshankumar7904800 · 1 day ago

Text

Clinical Trials Market

Clinical Trials Market Size, Share, Trends: IQVIA Leads

Acceptance of Virtual and Distributed Clinical Trials

Market Overview:

The global Clinical Trials Market is estimated to grow at a CAGR of 5.7% from USD 47.5 billion in 2022 to USD 78.3 billion by 2031. Throughout the forecast period, North America is expected to dominate the market. Advances in clinical trial technology, a growing need for innovative therapies, and an increase in the prevalence of chronic illnesses are driving significant expansion in the clinical study industry. Rising R&D investments by pharmaceutical companies, a greater emphasis on personalised therapy, and favourable legislative laws are all factors propelling market expansion even further. Nonetheless, rigorous rules, patient recruitment issues, and high costs may impede progress.

DOWNLOAD FREE SAMPLE

Market Trends:

Offering improved patient involvement and data collecting efficiency, the move towards distributed and virtual clinical trials is transforming the sector. The COVID-19 epidemic has sped this tendency as it required remote trial operations. Using digital technologies such as wearable devices, telemedicine, and electronic patient-reported outcomes (ePRO), decentralized trials help to allow remote patient monitoring and data collecting. This strategy lowers geographic obstacles and increases convenience, hence improving patient recruitment and retention. It also makes real-world data collecting possible and lets more varied patient groups exist. Decentralized trials are projected to proliferate as technology develops and regulatory authorities embrace new models, therefore transforming the field of clinical research.

Market Segmentation:

Phase III studies take front stage in the market, crucially in proving the safety and effectiveness of novel medicines in large patient groups. Usually including hundreds of people, these studies are carried out at many locations—often abroad. Phase III studies' complexity and scope demand large expenditures in data administration, regulatory compliance, and patient recruiting. Furthermore important for getting regulatory clearance and deciding if novel medications are commercially viable are the results of Phase III studies. The need for well-designed and well carried out Phase III studies is still strong as pharmaceutical firms keep concentrating on introducing new treatments to market, which drives the predominance of this category in the clinical trials market.

Market Key Players:

The clinical trials market is highly competitive, with major players focusing on improving their goods and expanding their geographical reach through strategic partnerships, mergers, and acquisitions. Key companies such as IQVIA, Parexel International Corporation, Pharmaceutical Product Development, LLC (PPD), Charles River Laboratories, ICON plc, Syneos Health, Medpace, Wuxi AppTec, PRA Health Sciences, Chiltern International Ltd., SGS SA, and Clinipace dominate the market.

Name: Hari Krishna

Email us: [email protected]

Website: https://aurorawaveintellects.com/

#market insights #market research #market trends

0 notes

clinicalstudy · 8 days ago

Text

Top Five Clinical Research Services in USA

The clinical research services are the vital link between research and development of effective medicine, fostering development in health care and enhancing the outcome of patients globally.

Clinical research services play a crucial role in advancing medical innovations and bringing life-changing treatments to market. Here are the top five clinical research organizations that are leading the way in the United States:

1.IQVIA IQVIA stands at the forefront of clinical research, with an impressive annual revenue of $13.87 billion and a workforce of 88,000 professionals. Founded in 1982 and headquartered in Durham, North Carolina, the company excels in integrating human science, technology, and data science to improve healthcare understanding

2.ProRelix Research As a standout clinical research organization, ProRelix Research has captured our attention with its exceptional approach to clinical trials. From our personal experience, their commitment to quality and transparency is truly remarkable. The company provides comprehensive drug development services across Phases 1-4, adhering to strict ICH-GCP principles. What sets ProRelix apart is their meticulous attention to patient well-being and their ability to execute clinical trials with precision.

Key Strengths of ProRelix Research:

Global service capability

Support for Phase 1-4 clinical trials

Strict compliance with international standards

Transparent and quality-driven approach

3.Parexel

Headquartered in Waltham, Massachusetts, Parexel is a powerhouse in clinical research with an annual revenue of $3 billion. The organization specializes in pharmaceutical clinical studies, offering a wide range of services including clinical data management, medical writing, and regulatory affairs consulting.

4.Syneos Health

Created through a merger of inVentiv Health and INC Research, Syneos Health offers comprehensive clinical development services. With a focus on late-stage clinical trials, the company provides innovative solutions across various healthcare sectors.

5.Medpace Holdings

Based in Cincinnati, Ohio, Medpace is a scientifically-driven organization supporting clinical trials from Phase 1 to 5. They offer a full range of services including medical writing, quality assurance, and clinical trial management.

Why Clinical Research Services Matter

Clinical research services are the backbone of medical innovation, enabling the development of groundbreaking treatments and therapies. These organizations play a critical role in:

Conducting rigorous medical studies

Ensuring patient safety

Advancing healthcare technologies

Supporting pharmaceutical and biotechnology companies

Choosing the Right Clinical Research Partner

When selecting a clinical research service, consider:

Expertise in your specific therapeutic area

Global reach and capabilities

Compliance with international standards

Track record of successful trials

Conclusion:

Clinical research services are the backbone of medical innovation, bridging scientific discoveries with life-changing treatments. Organizations like ProRelix Research are pioneering new approaches, leveraging advanced technologies and deep expertise to accelerate drug development. As healthcare challenges evolve, these services remain essential in transforming medical research, ensuring patient safety, and bringing hope to millions worldwide.

#Clinical Research Services

0 notes

digitalmore · 25 days ago

Text

#IFTTT #DigitalMore.co

0 notes

sudheervanguri · 1 month ago

Text

Work from Home CRA Job vacancies at Syneos Health Syneos Health is hiring Clinical Research Associates for remote positions in Hyderabad/Bangalore. Minimum 03 year of CRA experience required. Apply now for a chance to work with a leading biopharmaceutical solutions organization. Job Title: Clinical Research Associate I (CRA I) Job ID: 24005945 Location: India-Asia Pacific - IND-Home-Based Description: Syneos Health® is a leading fully integrated biopharmaceutical solutions organization focused on accelerating customer success. We are currently seeking Clinical Research Associates for remote positions in Hyderabad/Bangalore. Job responsibilities Performs site qualification, site initiation, interim monitoring, site management activities and close-out visits (performed on-site or remotely) ensuring regulatory, ICH-GCP and/or Good Pharmacoepidemiology Practice (GPP) and protocol compliance. Uses judgment and experience to evaluate overall performance of site and site staff and to provide recommendations regarding site-specific actions; immediately communicates/escalates serious issues to the project team and develops action plans. Maintains a working knowledge of ICH/GCP Guidelines or other applicable guidance, relevant regulations, and company SOPs/processes. Verifies the process of obtaining informed consent has been adequately performed and documented for each subject/patient, as required/appropriate. Demonstrates diligence in protecting the confidentiality of each subject/patient. Assesses factors that might affect subject/patient’s safety and clinical data integrity at an investigator/physician site such as protocol deviation/violations and pharmacovigilance issues. Per the Clinical Monitoring/Site Management Plan (CMP/SMP): Assesses site processes Conducts Source Document Review of appropriate site source documents and medical records Verifies required clinical data entered in the case report form (CRF) is accurate and complete Applies query resolution techniques remotely and on site, and provides guidance to site staff as necessary, driving query resolution to closure within agreed timelines Utilizes available hardware and software to support the effective conduct of the clinical study data review and capture Verifies site compliance with electronic data capture requirements May perform investigational product (IP) inventory, reconciliation and reviews storage and security. Verifies the IP has been dispensed and administered to subjects/patients according to the protocol. Verifies issues or risks associated with blinded or randomized information related to IP. Applies knowledge of GCP/local regulations and organizational procedures to ensure IP is appropriately (re)labelled, imported and released/returned. Routinely reviews the Investigator Site File (ISF) for accuracy, timeliness and completeness. Reconciles contents of the ISF with the Trial Master File (TMF). Ensures the investigator/physician site is aware of the requirement of archiving essential documents in accordance with local guidelines and regulations. Documents activities via confirmation letters, follow-up letters, trip reports, communication logs, and other required project documents as per SOPs and Clinical Monitoring Plan/Site Management Plan. Supports subject/patient recruitment, retention and awareness strategies. Enters data into tracking systems as required to track all observations, ongoing status and assigned action items to resolution. For assigned activities, understands project scope, budgets, and timelines; manages site-level activities / communication to ensure project objectives, deliverables and timelines are met. Must be able to quickly adapt to changing priorities to achieve goals / targets. May act as primary liaison with study site personnel, or in collaboration with Central Monitoring Associate. Ensures all assigned sites and project-specific site team members are trained and compliant with applicable requirements.

Prepares for and attends Investigator Meetings and/or sponsor face to face meetings. Participates in global clinical monitoring/project staff meetings (inclusive of Sponsor representation, as applicable) and attends clinical training sessions according to the project specific requirements. Provides guidance at the site and project level towards audit readiness standards and supports preparation for audit and required follow-up actions. Maintains a working knowledge of ICH/GCP Guidelines or other applicable guidance, relevant regulations, and company SOPs/processes; completes assigned training as required. For Real World Late Phase, the CRA II will use the business card title of Site Management Associate II. Additional responsibilities include: Site support throughout the study lifecycle from site identification through close-out Knowledge of local requirements for real world late phase study designs Chart abstraction activities and data collection Collaboration with Sponsor affiliates, medical science liaisons and local country staff The SMA II may be requested to train junior staff Identify and communicate out of scope activities to Lead CRA/Project Manager Proactively suggest potential sites based on local knowledge of treatment patterns, patient advocacy and Health Care Provider (HCP) associations Qualifications What we’re looking for Minimum 3yrs of experience in onsite monitoring and remote monitoring. Should have Neurology, immunology, rare diseases, CVD and Oncology therapeutic area experience preferred. Candidate from Mumbai, Delhi, Bengaluru, Hyderabad, Ahmedabad preferred. Bachelor’s degree or RN in a related field or equivalent combination of education, training and experience Knowledge of Good Clinical Practice/ICH Guidelines and other applicable regulatory requirements Must demonstrate good computer skills and be able to embrace new technologies Excellent communication, presentation and interpersonal skills Ability to manage required travel of up to 75% on a regular basis [caption id="attachment_66251" align="aligncenter" width="1200"] Work from Home Clinical Research Associate Opportunities at Syneos Health[/caption] Get to Know Syneos Health: Over the past 5 years, Syneos Health has worked with 94% of all Novel FDA Approved Drugs and 95% of EMA Authorized Products across 73,000 sites and 675,000+ trial patients. Join us in a highly competitive and ever-changing environment. Additional Information: Tasks, duties, and responsibilities as listed in this job description are not exhaustive. The company may assign other tasks as needed. Equivalent experience, skills, and education will also be considered. The company is committed to complying with applicable legislation and providing reasonable accommodations as needed. Apply now for a rewarding career opportunity with Syneos Health in the clinical research field! Apply online

0 notes

marketanalysisdata · 2 months ago

Text

Clinical Trials Market Comprehensive Analysis and Future Estimations by 2030

In 2023, the global clinical trials market was valued at USD 80.7 billion and is anticipated to grow at a compound annual growth rate (CAGR) of 6.49% from 2024 to 2030. Market growth was notably influenced by the COVID-19 pandemic, which in 2020 led to increased demand for both virtual and traditional clinical trials. Many companies made significant investments in developing new drugs to alleviate the burden of COVID-19 on healthcare systems. For instance, Synairgen plc and Parexel partnered on a Phase III study in 2020 to test the effectiveness of Interferon-beta (IFN-beta) treatment for COVID-19 patients. Additionally, technological advancements, a rising incidence of chronic diseases, the globalization of clinical trials, increased demand for personalized medicine, and a growing reliance on Contract Research Organizations (CROs) for conducting research activities are all expected to contribute to market growth.

The COVID-19 pandemic also brought about changes in how clinical trials were conducted, with regulatory agencies such as the U.S. FDA, European Medicines Agency (EMA), National Institutes of Health (NIH), and China’s National Medical Products Administration issuing guidelines to support decentralized and virtual clinical trials during the pandemic. This shift, along with the urgent need for new treatments, led to the adoption of fast-track clinical trials, providing new growth opportunities for the clinical trials market.

Gather more insights about the market drivers, restrains and growth of the Clinical Trials Market

Supportive government initiatives are another driver of market growth. For example, the World Health Organization (WHO) launched the Solidarity trial, an international effort to evaluate potential treatments for COVID-19 by comparing four treatments against the standard of care. In May 2020, WHO also announced an international coalition to develop multiple vaccine candidates simultaneously, naming this effort the Solidarity trial for vaccines.

Moreover, the increasing use of CRO services allows manufacturers and sponsors to focus on production capabilities and enhance in-house processes. CROs offer a wide range of services from drug discovery to post-marketing surveillance, which has simplified operations for small and mid-sized pharmaceutical and biotech companies by allowing them to outsource R&D activities, reducing infrastructure costs. For example, in November 2023, Syneos Health entered into an agreement with GoBroad Healthcare Group, expanding its clinical trial capabilities across multiple therapeutic areas in China.

Sponsors Segmentation Insights:

In 2023, pharmaceutical and biopharmaceutical companies accounted for the largest revenue share in the clinical trials market. This dominance is due to the industry’s high level of interest and financial investment in drug research and development. While basic research in academic labs is primarily funded by grants from the National Institutes of Health (NIH), the pharmaceutical industry bears the substantial costs associated with discovering and testing new drugs on animals and humans. Clinical trials represent a major expense, with the cost to bring a new drug to market ranging from USD 266 million to USD 802 million. In the U.S., approximately 75% of clinical trial funding comes from corporate sponsors.

The patient recruitment and retention segment captured a significant market share in 2023. The growing number of clinical studies worldwide has increased the demand for patient recruitment services. Increased funding for clinical research and widespread adoption of digital technologies are further supporting this growth. The market expansion is also driven by large investments in R&D, government support, and the presence of major CROs that provide comprehensive services, including patient recruitment, with active participation from multinational pharmaceutical and biopharmaceutical companies.

The data management segment also held a notable share in 2023 and is expected to maintain this trend over the forecast period. Growth in this segment is driven by the increasing adoption of data management services and a trend toward decentralized trials. The integration of advanced technologies like Artificial Intelligence (AI) and Machine Learning (ML) for data entry, analysis, and quality control is further expected to drive demand in this segment.

Order a free sample PDF of the Clinical Trials Market Intelligence Study, published by Grand View Research.

#Clinical Trials Market Share #Clinical Trials Market Analysis

0 notes

marketstudyreport · 2 months ago

Text

Clinical Trials Market Revenue, Share and Growth Rate to 2030

Gather more insights about the market drivers, restrains and growth of the Clinical Trials Market

Sponsors Segmentation Insights:

Order a free sample PDF of the Clinical Trials Market Intelligence Study, published by Grand View Research.

#Clinical Trials Market Share #Clinical Trials Market Analysis

0 notes

businessindustry · 2 months ago

Text

Pediatric Clinical Trial Market Forecast, Size 2024 to 2032

The Reports and Insights, a leading market research company, has recently releases report titled “Pediatric Clinical Trial Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032.” The study provides a detailed analysis of the industry, including the global Pediatric Clinical Trial Market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Report Highlights:

How big is the Pediatric Clinical Trial Market?

The global pediatric clinical trial market was valued at US$ 16.5 Billion in 2023 and is expected to register a CAGR of 6.6% over the forecast period and reach US$ 29.3 Billion in 2032.

What are Pediatric Clinical Trial?

A pediatric clinical trial is a research study aimed at assessing the safety, efficacy, and appropriate dosing of medical interventions—such as medications, vaccines, or medical devices—in children and adolescents. These trials are critical for understanding how treatments affect younger populations, as children can react differently than adults due to their unique physiological, developmental, and metabolic traits. Conducted under strict ethical guidelines to protect child participants, these trials typically require parental consent and child assent. Pediatric clinical trials are essential for creating age-appropriate therapies that address the specific health needs of children.

Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/2481

What are the growth prospects and trends in the Pediatric Clinical Trial industry?

The pediatric clinical trial market growth is driven by various factors and trends. The pediatric clinical trial market is experiencing growth, driven by a heightened emphasis on developing age-specific therapies and an increasing prevalence of pediatric diseases. Pharmaceutical companies and research organizations are recognizing the critical need to conduct clinical trials tailored specifically for children to ensure that medical treatments are both safe and effective for younger populations. Regulatory agencies are also stressing the importance of pediatric studies, resulting in greater investment in this field. Furthermore, advancements in technology and data analytics are enhancing trial design and patient recruitment, leading to more efficient studies. As the demand for customized pediatric healthcare continues to rise, the market for pediatric clinical trials is expected to expand significantly, facilitating the development of vital therapies for children. Hence, all these factors contribute to pediatric clinical trial market growth.

What is included in market segmentation?

The report has segmented the market into the following categories:

By Area

Oncology

Infectious Diseases

Cardiovascular Diseases

Metabolic Diseases

Respiratory Diseases

Diabetes

HIV

By Sponsor

Industry

Government Organizations

Non-Government Organizations

Associations

By Phases

Phase 1

Phase 2

Phase 3

Phase 4

North America

United States

Canada

Europe

Germany

United Kingdom

France

Italy

Spain

Russia

Poland

Benelux

Nordic

Rest of Europe

Asia Pacific

China<

Japan

India

South Korea

ASEAN

Australia & New Zealand

Rest of Asia Pacific

Latin America

Brazil

Mexico

Argentina

Middle East & Africa

Saudi Arabia

South Africa

United Arab Emirates

Israel

Rest of MEA

Who are the key players operating in the industry?

The report covers the major market players including:

Synteract

ICON Plc.

Syneos Health

Medpace, Inc

PPD Inc.

Premier Research

LabCorp Drug Development

QPS Holding

Pfizer Inc.

The Emmes Company, LLC

IQVIA Inc.

View Full Report: https://www.reportsandinsights.com/report/Pediatric Clinical Trial-market

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Reports and Insights Business Research Pvt. Ltd. 1820 Avenue M, Brooklyn, NY, 11230, United States Contact No: +1-(347)-748-1518 Email: [email protected] Website: https://www.reportsandinsights.com/ Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/ Follow us on twitter: https://twitter.com/ReportsandInsi1

#Pediatric Clinical Trial Market share #Pediatric Clinical Trial Market size #Pediatric Clinical Trial Market trends

0 notes

biotech-news-feed · 3 months ago

Link

Syneos Health lands former IQVIA R&D leader as CEO gmasson Wed, 10/09/2024 - 12:15 #BioTech #science

#Blockchain #Crypto

0 notes

tamanna31 · 3 months ago

Text

Clinical Trials 2024 Industry Size, Demands, Growth and Top Key Players Analysis Report

Clinical Trials Industry Overview

The global clinical trials market size was valued at USD 80.7 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.49% from 2024 to 2030.

The market growth spiked in 2020 owing to the COVID-19 pandemic. This growth pattern was witnessed by both virtual clinical trials and traditional ones. Several companies invested heavily in novel drug development to minimize COVID-19 patient burden. One such example being, in 2020, Synairgen plc and Parexel collaborated on a Phase III study of Interferon-beta (IFN-beta) treatment for COVID-19. Furthermore, rapid technological evolution, rising prevalence of chronic diseases, globalization of clinical trials, penetration of personalized medicine and a rise in demand for CROs for conducting research activities is expected to positively impact the market growth.

Gather more insights about the market drivers, restrains and growth of theClinical Trials Market

In addition, the COVID-19 pandemic led to changing the ways of conducting upcoming or ongoing clinical trials. Regulatory agencies including the U.S. FDA, the European Medicines Agency (EMA), the National Institutes of Health (NIH), and China’s National Medical Products Administration among several others issued various guidelines for conducting trials during the pandemic to support the implementation of decentralized clinical trials and virtual services. The current scenario for research and development activities across the globe and the need for several new treatment options have also led to the adoption of fast-track clinical trials. Thus, aforementioned factors are estimated to offer new avenues to the clinical trials market growth.

Favorable government support and initiatives is another aspect boosting the market growth potential. For instance, the WHO launched Solidarity, an international clinical trial to determine effective treatment against COVID-19. [PS2] It includes comparing four treatment options against the standard of care to evaluate their effectiveness against the coronavirus. In May 2020, the WHO also announced an international alliance for simultaneously developing multiple candidate vaccines to prevent the spread of the coronavirus disease, calling this effort the Solidarity trial for vaccines.

Furthermore, the use of CRO services helps manufacturers/sponsors pay complete attention to the production capacity and enhance their in-house processes. The availability of the vast array of services from drug discovery to post marketing surveillance has further simplified processes for mid-size & small-scale pharmaceutical and biotechnological organizations by providing them the option to outsource research and development activities to reduce infrastructure investment. For instance, in November 2023, Syneos Health signed an agreement with GoBroad Healthcare Group. This collaborative initiative extended the company’s clinical trial capabilities into a more extensive array of therapeutic areas in China.

Browse through Grand View Research's Healthcare IT Industry Research Reports.

The global digital neuro biomarkers market size was estimated at USD 593.1 million in 2023 and is projected to grow at a CAGR of 25.3% from 2024 to 2030.

The global healthcare digital experience platform market size was valued at USD 1.26 billion in 2023 and is forecasted to grow at a CAGR of 12.5% from 2024 to 2030.

Clinical Trials Market Segmentation

Grand View Research has segmented the global clinical trials market based on phase, study design, indication, sponsor, indication by study design, and region:

Clinical Trials Phase Outlook (Revenue, USD Billion, 2018 - 2030)

Phase I

Phase II

Phase III

Phase IV

Clinical Trials Study Design Outlook (Revenue, USD Billion, 2018 - 2030)

Interventional

Observational

Expanded Access

Clinical Trials Indication by Study Design Outlook (Revenue, USD Billion, 2018 - 2030)

Autoimmune/Inflammation

Rheumatoid Arthritis

Multiple Sclerosis

Osteoarthritis

Irritable Bowel Syndrome (IBS)

Others

Pain Management

Chronic Pain

Acute Pain

Oncology

Blood Cancer

Solid Tumors

Other

CNS Condition

Epilepsy

Parkinson's Disease (PD)

Huntington's Disease

Stroke

Traumatic Brain Injury (TBI)

Amyotrophic Lateral Sclerosis (ALS)

Muscle Regeneration

Others

Diabetes

Obesity

Cardiovascular

Others

Clinical Trials Indication Outlook (Revenue, USD Billion, 2018 - 2030)

Autoimmune/Inflammation

Interventional

Observational

Expanded Access

Pain Management

Interventional

Observational

Expanded Access

Oncology

Interventional

Observational

Expanded Access

CNS Condition

Interventional

Observational

Expanded Access

Diabetes

Interventional

Observational

Expanded Access

Obesity

Interventional

Observational

Expanded Access

Cardiovascular

Interventional

Observational

Expanded Access

Others

Interventional

Observational

Expanded Access

Clinical Trials Sponsor Outlook (Revenue, USD Billion, 2018 - 2030)

Pharmaceutical & Biopharmaceutical Companies

Medical Device Companies

Others

Clinical Trials Service Type Outlook (Revenue, USD Billion, 2018 - 2030)

Protocol Designing

Site Identification

Patient Recruitment

Laboratory Services

Bioanalytical Testing Services

Clinical Trial Data Management Services

Others

Clinical Trials Regional Outlook (Revenue, USD Billion, 2018 - 2030)

North America

Canada

Europe

Germany

France

Spain

Italy

Asia Pacific

India

Japan

China

Australia

South Korea

Latin America

Brazil

Mexico

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Key Companies profiled:

IQVIA

PAREXEL International Corporation

Pharmaceutical Product Development, LLC

Charles River Laboratory

ICON Plc

PRA Health Sciences

Syneos Health

Eli Lilly and Company

Novo Nordisk A/S

Pfizer

Clinipace

Recent Developments

In August 2023, Parexel & Partex entered a strategic partnership aimed at utilizing Artificial Intelligence (AI)-driven solutions to expedite the process of drug discovery and development for biopharmaceutical clients globally. The collaboration aimed to reduce risks associated with the assets in their respective portfolios.

In August 2023, Novo Nordisk announced to acquire Inversago Pharma. This acquisition was part of Novo Nordisk's strategic efforts to develop new therapies targeting individuals with obesity, diabetes, and other significant metabolic diseases

Order a free sample PDF of the Clinical Trials Market Intelligence Study, published by Grand View Research.

#Clinical Trials Market

0 notes

mj2994-me-blog · 3 months ago

Text

Pharmaceutical Contract Research Organization Market Market

Pharmaceutical Contract Research Organization Market Share Insights

Reed Intelligence has recently published a new report titled ""Global Pharmaceutical Contract Research Organization Market."" This comprehensive report delves into crucial aspects of the Bluetooth fingerprint scanner industry, offering valuable insights for both established and new market participants. It covers key factors such as market share, profitability, production, sales, manufacturing processes, advertising strategies, technological innovations, major industry players, and regional market breakdowns, among other important details.

Get Free Sample Report PDF @ https://reedintelligence.com/market-analysis/global-pharmaceutical-contract-research-organization-market/request-sample

Pharmaceutical Contract Research Organization Market Share by Key Players

IQVIA

Syneos Health

Quintiles

PPD

Parexel

ICON

PRA Health Sciences

InVentiv

INC Research Holdings

CRL

Wuxi AppTec

Charles River

Envigo

Medpace Holdings

SGS

PSI CRO

Axcent Advanced Analytics

BIO Agile Therapeutics

Firma Clinical Research

Acculab Lifesciences

Azelix

CTSERV

PEPGRA

The report also covers several important factors including strategic developments, government regulations, market analysis, and the profiles of end users and target audiences. Additionally, it examines the distribution network, branding strategies, product portfolios, market share, potential threats and barriers, growth drivers, and the latest industry trends.

Pharmaceutical Contract Research Organization Market Segmentation

The report on the Global Pharmaceutical Contract Research Organization Market offers a thorough segmentation by type, applications, and regions. It details production and manufacturing data for each segment over the forecast period from 2024 to 2032. The application segment focuses on the different uses and operational processes within the industry. Analyzing these segments will provide insights into the various factors contributing to market growth and their significance.

The report is segmented as follows:

Segment By Type

Active Pharmaceutical Ingredient

Finished Dosage Formulation

Segment By Application

Pharmaceutical and Biopharmaceutical Companies

Medical Device Companies

Academic Institutes

Pharmaceutical Contract Research Organization Market Segmentation by Region

North America

U.S

Canada

Europe

Germany

France

Asia Pacific

China

India

Japan

Australia

South Korea

Latin America

Brazil

Middle East & Africa

UAE

Kingdom of Saudi Arabia

South Africa

Get Detailed Segmentation @ https://reedintelligence.com/market-analysis/global-pharmaceutical-contract-research-organization-market/segmentation

The market research report on the Global Pharmaceutical Contract Research Organization Market has been thoughtfully compiled by examining a range of factors that influence its growth, including environmental, economic, social, technological, and political conditions across different regions. A detailed analysis of data related to revenue, production, and manufacturers provides a comprehensive view of the global landscape of the Pharmaceutical Contract Research Organization Market. This information will be valuable for both established companies and newcomers, helping them assess the investment opportunities in this growing market.

Key Highlights

The report delivers essential insights into the Global Pharmaceutical Contract Research Organization Market.

The report covers data for the years 2024-2032, highlighting key factors that impact the market during this period.

It emphasizes technological advancements, government regulations, and recent market developments.

The report will explore advertising and marketing strategies, examine market trends, and provide detailed analysis.

The report includes growth analysis and forecasts, with predictions extending up to the year 2032.

The report highlights a detailed statistical analysis of the key players in the market.

It presents a comprehensive and extensively researched overview of the market.

Buy Pharmaceutical Contract Research Organization Market Research Report @ https://reedintelligence.com/market-analysis/global-pharmaceutical-contract-research-organization-market/buy-now

Email: [email protected]

#Pharmaceutical Contract Research Organization Market Size #Pharmaceutical Contract Research Organization Market Share #Pharmaceutical Contract Research Organization Market Growth #Pharmaceutical Contract Research Organization Market Trends #Pharmaceutical Contract Research Organization Market Players

0 notes

ashwetu · 5 months ago

Text

Meticulous Research® Releases In-Depth Analysis on Global Clinical Trials Market, Forecasting Growth to $102.20 Billion by 2031

Meticulous Research®, a renowned global market research company, has published a comprehensive report titled, "Clinical Trials Market Size, Share, Forecast, & Trends Analysis by Service (Consulting, Patient Recruitment, Data Management, Regulatory, Site Support), Therapeutic Area (Oncology, Cardiology, Diabetes, Dermatology), Phase, End User - Global Forecast to 2031." This report provides a detailed examination of the global clinical trials market, which is projected to reach $102.20 billion by 2031, expanding at a CAGR of 7.2% from 2024 to 2031.

Key Market Drivers and Challenges

The clinical trials market is experiencing robust growth due to several pivotal factors:

Focus on Rare Diseases: An increasing emphasis on developing treatments for rare diseases is driving market growth.

Adoption of Personalized Medicine: The growing adoption of personalized medicine is fueling demand for specialized clinical trials.

R&D Expenditure: Rising investments in research and development are accelerating the number of clinical trials conducted globally.

Improved Recruitment Processes: Enhanced recruitment and retention strategies are leading to more efficient clinical trials.

Download Sample Report Here: https://www.meticulousresearch.com/download-sample-report/cp_id=5934

However, the market faces challenges such as the time-intensive nature of clinical trials, stringent regulations, and evolving legal frameworks, which add complexity to the process.

Emerging Opportunities and Trends

The clinical trials market is poised for significant growth opportunities, particularly in the following areas:

Patient-Centric Trials: The integration of the Internet of Medical Things (IoMT) is enabling more patient-centered approaches in clinical trials.

Cloud-Based Pharmacovigilance: Advancements in cloud technology are revolutionizing pharmacovigilance practices, ensuring better safety monitoring.

AI Integration: The use of artificial intelligence in clinical trials, from patient recruitment to data analytics, is transforming the industry.

Notable market trends include the incorporation of digital health technologies, wearable devices, automation, and decentralized clinical trials. Additionally, AI-driven modeling for patient enrichment and recruitment is gaining traction, alongside AI-enabled analytics for clinical trial management.

Leading Industry Players

The global clinical trials market is dominated by key players, including:

Laboratory Corporation of America Holdings (U.S.)

Medpace, Inc. (U.S.)

Charles River Laboratories International, Inc. (U.S.)

IQVIA Inc. (U.S.)

Parexel International Corporation (U.S.)

Syneos Health (U.S.)

ICON plc (Ireland)

WuXi AppTec Co., Ltd. (China)

Thermo Fisher Scientific Inc. (U.S.)

Fortrea Inc. (U.S.)

Celerion Inc. (U.S.)

Novotech Health Holdings (Australia)

SGS Société Générale de Surveillance SA (Switzerland)

CTI Clinical Trial and Consulting, Inc. (U.S.)

Linical USA, Inc. (U.S.)

Quick Buy: https://www.meticulousresearch.com/Checkout/42238521

Market Segmentation and Regional Insights

The clinical trials market is segmented into phases, service types, therapeutic areas, end users, and geography. Key segments include:

Phase III Trials: Expected to dominate in 2024 with a market share exceeding 68.4%, driven by the large number of participants, extended trial durations, and significant financial investments.

Oncology Therapeutics: Forecasted to lead the therapeutic areas with over 33.2% market share in 2024, propelled by the rising incidence of cancer and increased research efforts.

Geographically, North America is set to maintain the largest market share, accounting for over 41.6% in 2024. This dominance is attributed to substantial R&D investments, the early adoption of new technologies in clinical trials, and the presence of major market players. For instance, Syneos Health (U.S.) and uMotif Limited (U.K.) have recently collaborated to enhance clinical trials through digital innovations, including Electronic Patient-reported Outcomes (ePRO) and Electronic Clinical Outcome Assessments (eCOA).

Request Sample Report Here: https://www.meticulousresearch.com/request-sample-report/cp_id=5934

Key Questions Addressed in the Report:

What are the high-growth market segments in terms of phase, service type, therapeutic area, end user, and region/country?

What was the historical market size for clinical trials globally?

What are the market forecasts and estimates for 2024–2031?

What are the major drivers, restraints, challenges, opportunities, and trends in the global clinical trials market?

Who are the key competitors, and what strategies do they employ?

What are the recent developments and geographical trends in the market?

Contact Meticulous Research®

For further inquiries or detailed insights:

Email: [email protected]

Phone: +1-646-781-8004

0 notes

health-views-updates · 5 months ago

Text

Functional Service Providers Market Trends: Future Insights and Predictions

Functional Service Providers Market Outlook, Scope & Overview:

Industry reports indicate that the global functional service providers market was valued at USD 14.58 billion in 2022 and is projected to reach USD 26.98 billion by 2030, growing at a CAGR of 8% over the forecast period 2023-2030.

Technological Advancements to Drive Growth of Global Functional Service Providers Market

The adoption of functional service providers (FSP) will continue to influence global market revenues. Pharmaceutical and biotechnology companies are increasingly utilizing FSPs to enhance operational efficiency, reduce costs, and focus on core competencies.

As a service segment, clinical trial management currently holds a significant share of the global functional service providers market. This segment is anticipated to grow at a year-over-year rate of 8% in 2023 over 2022 and reach USD 26.98 billion in revenues by 2030. The increasing complexity of clinical trials, coupled with advancements in clinical research methodologies, is expected to drive market growth.

Get a Free Sample Report of Vitamins Market: https://www.snsinsider.com/sample-request/2481

Functional Service Providers – Market Dynamics

Drivers:

Functional service providers are witnessing significant growth in the global market due to their ability to provide specialized expertise, scalable resources, and cost-effective solutions for clinical development and other pharmaceutical services. The growing trend of outsourcing non-core activities in the pharmaceutical and biotechnology industries, coupled with the increasing need for compliance with regulatory requirements, are key factors driving the adoption of FSPs worldwide. Additionally, the rising demand for efficient and timely drug development processes is further propelling market growth.

Restraints:

Despite the growth potential, challenges such as data security concerns, the complexity of managing outsourced services, and the need for seamless integration with internal processes are hindering the widespread adoption of functional service providers. Moreover, the variability in quality and performance among service providers and the need for robust contract management pose additional challenges to market expansion.

Functional Service Providers – Market Outlook

The proven benefits of functional service providers in enhancing operational efficiency, reducing time-to-market for new drugs, and ensuring regulatory compliance have contributed to the market's growth. Functional service providers are expected to witness increased adoption across major pharmaceutical markets, including North America, Europe, and Asia Pacific, driven by advancements in clinical research and the growing focus on strategic outsourcing.

Global Functional Service Providers Market

The rise in demand for functional service providers in developed and emerging markets is expected to drive market growth over the forecast period. North America currently holds a significant market share in the global functional service providers market, with the US being a key contributor to market revenues. Europe and Asia Pacific regions are also experiencing rapid adoption of FSPs, supported by favorable regulatory frameworks and increasing investments in pharmaceutical research and development.

Key Players in the Functional Service Providers Market

Leading companies in the functional service providers market include IQVIA, PAREXEL International Corporation, ICON plc, and Syneos Health. These companies are at the forefront of providing advanced FSP solutions for various pharmaceutical services, including clinical trial management, data management, and pharmacovigilance.

In conclusion, the global functional service providers market is poised for substantial growth over the forecast period, driven by technological advancements, increasing pharmaceutical outsourcing, and the expanding adoption of specialized service providers across diverse pharmaceutical and biotechnology settings.

Other Trending Reports

Diabetic Nephropathy Industry Growth

Nano Biotechnology Industry Growth

Patient Engagement Solutions Industry Growth

Blood Glucose Monitoring Device Industry Growth

#Functional Service Providers Market #Functional Service Providers Market Size #Functional Service Providers Market Share #Functional Service Providers Market Trends #Functional Service Providers Market Growth #Functional Service Providers Market Analysis #Functional Service Providers Market Outlook

0 notes

sudheervanguri · 3 months ago

Text

Syneos Health Hiring Statistical Programmers Are you passionate about data analysis and programming in the biopharmaceutical industry? Syneos Health, a leader in biopharmaceutical solutions, is actively seeking Statistical Programmers (I and II levels) to join their team. This role is ideal for professionals with experience in SAS programming and a strong desire to work on innovative clinical trials. Location: India (Home-Based) Vacancy: Statistical Programmers (I/II) About Syneos Health At Syneos Health, we are driven by a mission to accelerate customer success in clinical development, medical affairs, and commercialization. Our team of over 29,000 employees, spanning 110 countries, plays a vital role in delivering cutting-edge therapies and innovations. As a Statistical Programmer, you will contribute to the success of global biopharmaceutical projects and have the opportunity to grow your career in a fast-paced, dynamic environment. Key Responsibilities of the Role As a Statistical Programmer I/II, you will: Use SAS or other programming tools to generate summary tables, data listings, graphs, and derived datasets as outlined in the statistical analysis plan. Collaborate with Biostatisticians and other team members to ensure outputs meet high-quality standards. Perform validation programming and resolve discrepancies to ensure data accuracy. Manage multiple projects and timelines, adapting to changes and maintaining thorough project documentation. Adhere to SOPs, work instructions, and relevant regulatory guidelines (e.g., ICH) to ensure compliance. Contribute ideas in internal meetings and assist team members as needed to meet business goals. [caption id="attachment_106029" align="aligncenter" width="640"] Syneos Health®: Hiring Statistical Programmers (I/II)[/caption] Qualifications they Are Looking For To succeed in this role, you’ll need: An Undergraduate Degree in a scientific or statistical discipline. Equivalent programming experience may be considered. Proficiency in SAS programming, preferably in a clinical trial environment. Strong communication skills in English – both written and verbal. Ability to work effectively across multiple projects and manage time efficiently. Apply Today! Apply Here: Syneos Health Careers - Statistical Programmers I/II

0 notes

tritonmarketresearchamey · 5 months ago

Text

Clinical Trials Support Services Market: Growth & Prospects

Major regulatory authorities worldwide mandate pharmaceutical, biotech, and medical device companies to conduct clinical trials prior to introducing any new drug, vaccine, therapy, or product to assess their probable outcomes. However, executing these trials is a rigorous process associated with several challenges. Several solution providers focus on offering support services to contract research organizations (CROs) that help to streamline processes. Experts at Triton Market Research estimate the global clinical trials support services market will progress with a CAGR of 7.84% in the forecast period from 2022 to 2028.

Disease incidence across the globe is surging rapidly. According to National Cancer Institute, annually reported cancer cases are expected to rise from 18.1 million in 2018 to 29.5 million by 2040. This necessitates an increased focus on developing treatment modalities, which would support the growth of the studied market.

Status of Clinical Trials across Regional Markets

Spain ranks fourth globally in terms of conducting clinical trials. In 2020, the top therapy areas for industry-sponsored trials in the country were cancer, infectious diseases, CNS disorders, respiratory ailments, and immunological conditions. That year, 1,019 trials received approval, of which 34% of the share was captured by oncology treatment drugs.

Thailand is an emerging hotspot for organizations to perform clinical studies because of its highly developed infrastructure, universal healthcare system, and supportive policies. Besides, the nation also boasts of a highly skilled workforce and a significant presence of research-based pharmaceutical companies and CROs.

Whereas, Turkey is working to achieve global competitiveness for performing clinical research, with rising attention from international players like Bayer AG, Takeda, and Janssen Pharmaceuticals. The vast majority of the trials conducted here are in phases II and III. The capabilities of its R&D centers and the efficacy of their results, make the nation an important research hub.

These developments imply enhanced adoption of support services in Europe, the Asia-Pacific, and the Middle East and Africa in the years to come.

Key Support Services in Demand

Data Management is expected to evolve the fastest, with a 10.26% CAGR

Clinical data management involves data collection, database design, CRF tracking & annotation, medical coding, etc. With growing data generation, it becomes essential to use data management systems to easily record data, minimize errors, and protect from data loss, among others. “Oracle Clinical,” “Macro,” “Clintrial,” and “Rave” are some systems that have gained immense popularity.

Clinical Trial Site Management accounted for the largest revenue share of $3624.69 million in 2021

Site management systems are required for effectively monitoring research sites and ensuring continuous communication between stakeholders. Clinical Conductor, offered by Advarra Inc, is a comprehensive trial management system that aids in optimizing finances, ensuring regulatory compliance, and managing overall operations for research sites, networks, and healthcare institutions.

Market Players gain Leverage with Growth-oriented Strategies

In September 2021, Syneos Health acquired StudyKIK, a leading clinical trial recruitment and retention company. This acquisition will further help the company to boost its ability to deliver tech-enabled, insight-powered solutions to improve patient experience.

In October 2021, Parexel and Kyoto University Hospital announced a strategic collaboration aimed at providing more opportunities for clinical research and developing efficient solutions for supporting clinical studies.

In April 2022, Advanced Clinical announced its continued expansion in Europe by opening its new office in Switzerland, with a view to fully support the company’s current and new clients located in the country and also access its skilled talent pool.

Paving the way for Future amid Challenges

Stringent guidelines are issued by supervisory bodies to ensure that medical products are safe for consumption. Sometimes, ensuring that research institutions adhere to the required standards exceeds the set timelines. These delays are a major challenge for the institutions, especially as they increase the costs incurred.

However, incorporating tech-based services and solutions for regulatory purposes has made the overall trial processes more robust and efficient by saving time and money. For instance, ICON Plc offers support services that combine its operational expertise with extensive regulatory intelligence to ensure that the trials are in sync with the latest recommendations by administrative agencies.

Further, companies and CROs are increasingly preferring Japan to conduct clinical research, as the country’s regulatory frameworks now emphasize aligning their approval timelines with those in the United States and European nations. The regulative environment in South Africa has also changed drastically in recent years, with government policies being much more supportive. These favorable developments are indicative of positive prospects for the clinical trials support services market.

FAQs:

Q 1) Which are the main segments covered in the report?

The key segments covered in the global clinical trials support services market are Phase Type, Service, and Sponsor.

Q 2) Which are the key regions in the global clinical trials support services market?

The Asia-Pacific (fastest expected growth) and North America (highest revenue share).

#Clinical Trials #Support Services Market #Lifesciences #triton market research #market research reports

0 notes